• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症中的表观遗传调控。

Epigenetic regulation in cancer.

作者信息

Gu Minzhi, Ren Bo, Fang Yuan, Ren Jie, Liu Xiaohong, Wang Xing, Zhou Feihan, Xiao Ruiling, Luo Xiyuan, You Lei, Zhao Yupei

机构信息

Department of General Surgery Peking Union Medical College Hospital Peking Union Medical College Chinese Academy of Medical Sciences Beijing P. R. China.

Key Laboratory of Research in Pancreatic Tumor Chinese Academy of Medical Sciences Beijing P. R. China.

出版信息

MedComm (2020). 2024 Feb 19;5(2):e495. doi: 10.1002/mco2.495. eCollection 2024 Feb.

DOI:10.1002/mco2.495
PMID:38374872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10876210/
Abstract

Epigenetic modifications are defined as heritable changes in gene activity that do not involve changes in the underlying DNA sequence. The oncogenic process is driven by the accumulation of alterations that impact genome's structure and function. Genetic mutations, which directly disrupt the DNA sequence, are complemented by epigenetic modifications that modulate gene expression, thereby facilitating the acquisition of malignant characteristics. Principals among these epigenetic changes are shifts in DNA methylation and histone mark patterns, which promote tumor development and metastasis. Notably, the reversible nature of epigenetic alterations, as opposed to the permanence of genetic changes, positions the epigenetic machinery as a prime target in the discovery of novel therapeutics. Our review delves into the complexities of epigenetic regulation, exploring its profound effects on tumor initiation, metastatic behavior, metabolic pathways, and the tumor microenvironment. We place a particular emphasis on the dysregulation at each level of epigenetic modulation, including but not limited to, the aberrations in enzymes responsible for DNA methylation and histone modification, subunit loss or fusions in chromatin remodeling complexes, and the disturbances in higher-order chromatin structure. Finally, we also evaluate therapeutic approaches that leverage the growing understanding of chromatin dysregulation, offering new avenues for cancer treatment.

摘要

表观遗传修饰被定义为基因活性的可遗传变化,这些变化不涉及潜在DNA序列的改变。致癌过程是由影响基因组结构和功能的改变积累所驱动的。直接破坏DNA序列的基因突变,辅以调节基因表达的表观遗传修饰,从而促进恶性特征的获得。这些表观遗传变化的主要方面是DNA甲基化和组蛋白标记模式的改变,它们促进肿瘤的发展和转移。值得注意的是,与基因变化的永久性相反,表观遗传改变的可逆性使表观遗传机制成为发现新型治疗方法的主要靶点。我们的综述深入探讨了表观遗传调控的复杂性,探索其对肿瘤发生、转移行为、代谢途径和肿瘤微环境的深远影响。我们特别强调表观遗传调控各层面的失调,包括但不限于负责DNA甲基化和组蛋白修饰的酶的异常、染色质重塑复合物中的亚基缺失或融合,以及高阶染色质结构的紊乱。最后,我们还评估了利用对染色质失调日益深入的理解的治疗方法,为癌症治疗提供了新途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/ba0d55dd3df4/MCO2-5-e495-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/28647f822fad/MCO2-5-e495-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/09c5d052adf5/MCO2-5-e495-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/ba0d55dd3df4/MCO2-5-e495-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/28647f822fad/MCO2-5-e495-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/09c5d052adf5/MCO2-5-e495-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/ba0d55dd3df4/MCO2-5-e495-g004.jpg

相似文献

1
Epigenetic regulation in cancer.癌症中的表观遗传调控。
MedComm (2020). 2024 Feb 19;5(2):e495. doi: 10.1002/mco2.495. eCollection 2024 Feb.
2
Epigenomics in stress tolerance of plants under the climate change.植物在气候变化下的应激耐受中的表观基因组学。
Mol Biol Rep. 2023 Jul;50(7):6201-6216. doi: 10.1007/s11033-023-08539-6. Epub 2023 Jun 9.
3
Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review.口腔鳞状细胞癌微环境中的表观遗传调控:综述
Cancers (Basel). 2023 Nov 27;15(23):5600. doi: 10.3390/cancers15235600.
4
Cancer epigenetics in clinical practice.癌症表观遗传学在临床实践中的应用。
CA Cancer J Clin. 2023 Jul-Aug;73(4):376-424. doi: 10.3322/caac.21765. Epub 2022 Dec 13.
5
MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer.微小RNA对乳腺癌中表观遗传修饰因子的调控
Cancers (Basel). 2019 Jun 27;11(7):897. doi: 10.3390/cancers11070897.
6
Analytical and therapeutic profiles of DNA methylation alterations in cancer; an overview of changes in chromatin arrangement and alterations in histone surfaces.癌症中 DNA 甲基化改变的分析和治疗特征;染色质排列变化和组蛋白表面改变概述。
Horm Mol Biol Clin Investig. 2023 Feb 17;44(3):337-356. doi: 10.1515/hmbci-2022-0043. eCollection 2023 Sep 1.
7
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.代谢重编程与癌症表观遗传学的串扰:机制与治疗机会的更新。
Cancer Commun (Lond). 2022 Nov;42(11):1049-1082. doi: 10.1002/cac2.12374. Epub 2022 Oct 20.
8
The epigenomics of sarcoma.肉瘤的表观基因组学。
Nat Rev Cancer. 2020 Oct;20(10):608-623. doi: 10.1038/s41568-020-0288-4. Epub 2020 Aug 11.
9
Targeting Chromatin Remodeling for Cancer Therapy.靶向染色质重塑治疗癌症。
Curr Mol Pharmacol. 2019;12(3):215-229. doi: 10.2174/1874467212666190215112915.
10
Effect of non-enzymatic glycosylation in the epigenetics of cancer.非酶糖基化在癌症表观遗传学中的作用。
Semin Cancer Biol. 2022 Aug;83:543-555. doi: 10.1016/j.semcancer.2020.11.019. Epub 2020 Dec 2.

引用本文的文献

1
CRISPR/dCas9-TET1-mediated epigenetic editing reactivates miR-200c in breast cancer cells.CRISPR/dCas9-TET1介导的表观遗传编辑可使乳腺癌细胞中的miR-200c重新激活。
Sci Rep. 2025 Aug 28;15(1):31739. doi: 10.1038/s41598-025-16911-8.
2
Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies.表观遗传调控与骨转移:不断发展的治疗策略
Pharmaceuticals (Basel). 2025 Jul 31;18(8):1140. doi: 10.3390/ph18081140.
3
Deciphering Medulloblastoma: Epigenetic and Metabolic Changes Driving Tumorigenesis and Treatment Outcomes.

本文引用的文献

1
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs.DNA 低甲基化使早期前列腺癌和 CTCs 中的抗肿瘤免疫基因沉默。
Cell. 2023 Jun 22;186(13):2765-2782.e28. doi: 10.1016/j.cell.2023.05.028. Epub 2023 Jun 15.
2
Metastasis.转移。
Cell. 2023 Apr 13;186(8):1564-1579. doi: 10.1016/j.cell.2023.03.003.
3
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.吉西他滨联合阿替利珠单抗治疗初始免疫检查点抑制剂治疗后进展的转移性尿路上皮癌的 II 期临床试验。
解读髓母细胞瘤:驱动肿瘤发生和治疗结果的表观遗传与代谢变化
Biomedicines. 2025 Aug 4;13(8):1898. doi: 10.3390/biomedicines13081898.
4
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies.癌症中的表观遗传失调:机制、诊断生物标志物及治疗策略
Med Oncol. 2025 Jul 21;42(8):359. doi: 10.1007/s12032-025-02905-z.
5
Current Bioinformatics Tools in Precision Oncology.精准肿瘤学中的当前生物信息学工具
MedComm (2020). 2025 Jul 9;6(7):e70243. doi: 10.1002/mco2.70243. eCollection 2025 Jul.
6
The role of abnormal epigenetic regulation of small GTPases in glioma (Review).小GTP酶异常表观遗传调控在神经胶质瘤中的作用(综述)
Int J Oncol. 2025 Aug;67(2). doi: 10.3892/ijo.2025.5769. Epub 2025 Jul 4.
7
Valproic acid exposure alters histone deacetylase mRNA expression profile in oral cancer and premalignant cell lines.丙戊酸暴露会改变口腔癌及癌前细胞系中组蛋白去乙酰化酶的mRNA表达谱。
Biomed Rep. 2025 Jun 11;23(2):135. doi: 10.3892/br.2025.2013. eCollection 2025 Aug.
8
Epigenetic regulators in cancer therapy and progression.癌症治疗与进展中的表观遗传调控因子
NPJ Precis Oncol. 2025 Jun 28;9(1):206. doi: 10.1038/s41698-025-01003-7.
9
Clinical Model Based on DR3 Promoter Methylation for Predicting Short-Term Mortality in Patients with Acute-on-Chronic Hepatitis B Liver Failure.基于DR3启动子甲基化的临床模型预测慢性乙型肝炎急性肝衰竭患者短期死亡率
Int J Gen Med. 2025 Jun 19;18:3253-3266. doi: 10.2147/IJGM.S525424. eCollection 2025.
10
Case Report: FAP fibroblasts and SPP1 macrophages in SMARCA2-deficient while SMARCA4-preserved poorly differentiated lung adenocarcinoma: two case reports and multi-omics analysis.病例报告:SMARCA2缺陷而SMARCA4保留的低分化肺腺癌中的FAP成纤维细胞和SPP1巨噬细胞:两例报告及多组学分析
Front Immunol. 2025 May 16;16:1568556. doi: 10.3389/fimmu.2025.1568556. eCollection 2025.
Clin Cancer Res. 2023 Jun 1;29(11):2052-2065. doi: 10.1158/1078-0432.CCR-22-3642.
4
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.不断演变的肿瘤微环境:从癌症起始到转移灶生长
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
5
Epigenetics as a mediator of plasticity in cancer.表观遗传学作为癌症可塑性的介体。
Science. 2023 Feb 10;379(6632):eaaw3835. doi: 10.1126/science.aaw3835.
6
The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.BRD4 抑制剂 JQ1 增强了阿贝西利在胃癌临床前模型中的抗肿瘤疗效。
J Exp Clin Cancer Res. 2023 Feb 9;42(1):44. doi: 10.1186/s13046-023-02615-2.
7
Acetyl-CoA metabolism in cancer.乙酰辅酶 A 在癌症中的代谢。
Nat Rev Cancer. 2023 Mar;23(3):156-172. doi: 10.1038/s41568-022-00543-5. Epub 2023 Jan 19.
8
DNA Methylation-Mediated Overexpression of in -Induced Gastric Cancer: In Silico- and In Vitro-Based Identification of a Potential Biomarker for Carcinogenesis.DNA 甲基化介导的 在 - 诱导胃癌中的过表达:基于计算机模拟和体外实验的致癌潜在生物标志物鉴定。
Int J Mol Sci. 2023 Jan 2;24(1):795. doi: 10.3390/ijms24010795.
9
Cancer epigenetics in clinical practice.癌症表观遗传学在临床实践中的应用。
CA Cancer J Clin. 2023 Jul-Aug;73(4):376-424. doi: 10.3322/caac.21765. Epub 2022 Dec 13.
10
EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.EZH2-H3K27me3 介导的 KRT14 上调促进三阴性乳腺癌腹膜转移。
Nat Commun. 2022 Nov 29;13(1):7344. doi: 10.1038/s41467-022-35059-x.